Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study

201536 citationsJournal Article

Authors

Hisashi Yamanaka · Tokyo Women's Medical University

Shouhei Nagaoka · Yokohama Minami Kyosai Hospital

Soo-Kon Lee · Yonsei University

Sang‐Cheol Bae · Hanyang University Seoul Hospital

Tsuyoshi Kasama · Showa University Hospital

Hitomi Kobayashi · Mie Chuo Medical Center

Yuichi Nishioka

Abstract

ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Systemic Lupus Erythematosus Research Monoclonal and Polyclonal Antibodies Research

Publication Details

Published in: Modern Rheumatology

Volume 26, Issue 5, pp. 651-661

DOI: 10.3109/14397595.2015.1123349

Field-Weighted Citation Impact: 2.13

Command Palette

Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study

Authors

Abstract

Topics & Keywords

Publication Details